Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The allergen-directed immune response is a complex physiological process characterized by the immune system's hypersensitivity to environmental allergens. This response is primarily driven by the Type I hypersensitivity pathway, where B cells produce allergen-specific Immunoglobulin E (IgE) that binds to high-affinity FcεRI receptors on mast cells and basophils (Galli et al., 2008, Nature). Upon subsequent exposure, allergen cross-linking of these IgE molecules triggers the release of inflammatory mediators like histamine and leukotrienes, as well as Th2 cytokines such as IL-4, IL-5, and IL-13 (Gould & Sutton, 2008, Nature Reviews Immunology). These mediators lead to the clinical symptoms of allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis (Pawankar et al., 2011, WAO White Book on Allergy). Therapeutic strategies targeting this response include monoclonal antibodies that neutralize IgE or inhibit cytokine signaling, as well as allergen-specific immunotherapy (AIT) designed to shift the immune profile toward tolerance (Akdis & Akdis, 2014, Nature Reviews Drug Discovery). Monitoring this response often involves measuring specific IgE levels and eosinophil counts to assess disease severity and treatment efficacy (Holgate, 2012, Nature Medicine). Safety concerns primarily involve the risk of anaphylaxis during allergen exposure or immunotherapy.
Modulation of the allergic cascade through several pathways: sequestration of free IgE to prevent mast cell sensitization, blockade of Th2-promoting cytokines (IL-4, IL-5, IL-13) or their receptors to reduce eosinophilia and airway hyperresponsiveness, and the induction of immune tolerance via allergen-specific immunotherapy (AIT), which promotes the production of IgG4 blocking antibodies and regulatory T cells (Akdis & Akdis, 2014, Nature Reviews Drug Discovery; Galli et al., 2008, Nature).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-directed immune response.